AbCellera Biologics Inc.
News
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Recommendation of "Moderate Buy" from Analysts
Ticker Report Shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat...\n more…
CEO, President & Chairperson of AbCellera Biologics Carl Hansen Buys More Stock
Simply Wall St AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders (or potential shareholders) will be happy to see that the CEO...\n more…
AbCellera to Present at Upcoming Investor Conferences in September
Business Wire AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 5, 2024...\n more…
AbCellera Biologics (NASDAQ:ABCL) Downgraded to "Hold" at Benchmark
Ticker Report Benchmark lowered shares of AbCellera Biologics (NASDAQ:ABCL - Free Report) from a buy rating to a hold rating in a research note published on Tuesday morning, MarketBeat Ratings reports. Separately...\n more…
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Consensus Price Target from Brokerages
Ticker Report AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has received an average rating of "Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Six equities research...\n more…
AbCellera Biologics Inc. (NASDAQ:ABCL) to Post FY2026 Earnings of ($0.63) Per Share, Leerink Partnrs Forecasts
Ticker Report AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Investment analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for AbCellera Biologics in a report released on Tuesday...\n more…